» Articles » PMID: 17706489

Kasai Portoenterostomy: 12-year Experience with a Novel Adjuvant Therapy Regimen

Overview
Journal J Pediatr Surg
Date 2007 Aug 21
PMID 17706489
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The role of adjuvant therapy with corticosteroids and choleretics after Kasai portoenterostomy for biliary atresia (BA) remains uncertain. Experience with a novel postoperative adjuvant therapy regimen is reported.

Methods: Between 1994 and 2006, 71 infants with BA were referred. Four died from uncorrectable congenital heart disease/cardiorespiratory failure without undergoing portoenterostomy, 7 underwent primary liver transplantation (3 referred > or = 19 weeks of age), and 60 underwent portoenterostomy at a median of 51 (10-104) days. Of these, 55 (92%) had type 3 BA and 6 had the BA splenic malformation syndrome. Fifty (83%) received the following adjuvant therapy beginning on postoperative day 5: oral dexamethasone 0.3 mg/kg bd for 5 days, 0.2 mg/kg bd for 5 days, and 0.1 mg/kg bd for 5 days together with oral ursodeoxycholic acid 5 mg/kg bd and phenobarbitone 5 mg/kg nocte, both of which were continued for 1 year. All infants received routine perioperative prophylactic antibiotics.

Results: Overall, 42 of 60 (70%) infants cleared their jaundice (bilirubin < 20 micromol/L): 38 of 50 (76%) with the dexamethasone/ursodeoxycholic acid regimen compared with 4 of 10 (40%) not receiving this adjuvant treatment. There were 4 late deaths after portoenterostomy: 2 from associated congenital disorders and 2 after liver transplantation. Of the remaining 56 children, 39 (70%) are currently alive with their native liver at a median follow-up of 3.3 years and 17 are alive after liver transplantation. Surgical complications occurred in 3 after portoenterostomy: adhesive bowel obstruction (2) and an anastomotic leak. One infant had gastrointestinal bleeding that may have been related to dexamethasone, but this resolved with ranitidine. There were no perioperative septic complications.

Conclusion: In this series, adjuvant postoperative treatment with a short course of oral dexamethasone and longer-term ursodeoxycholic acid significantly improved the outcome after Kasai portoenterostomy.

Citing Articles

Biliary atresia and congenital disorders of the extrahepatic bile ducts.

Islek A, Tumgor G World J Gastrointest Pharmacol Ther. 2022; 13(4):33-46.

PMID: 36051179 PMC: 9297290. DOI: 10.4292/wjgpt.v13.i4.33.


The incidence of different forms of ileus following surgery for abdominal birth defects in infants: a systematic review with a meta-analysis method.

Eeftinck Schattenkerk L, Musters G, Nijssen D, de Jonge W, de Vries R, van Heurn L Innov Surg Sci. 2022; 6(4):127-150.

PMID: 35937853 PMC: 9294340. DOI: 10.1515/iss-2020-0042.


Direct health care cost of treatment and medication of biliary atresia patients using the National Database of Health Insurance Claims and Specific Health Checkups.

Hoshino E, Konomura K, Obatake M, Moriwaki K, Sakai M, Urayama K Pediatr Surg Int. 2022; 38(4):547-554.

PMID: 35165784 PMC: 8913443. DOI: 10.1007/s00383-022-05079-1.


Cholangitis Definition and Treatment after Kasai Hepatoportoenterostomy for Biliary Atresia: A Delphi Process and International Expert Panel.

Calinescu A, Madadi-Sanjani O, Mack C, Schreiber R, Superina R, Kelly D J Clin Med. 2022; 11(3).

PMID: 35159946 PMC: 8836553. DOI: 10.3390/jcm11030494.


Analysis of Cholangitis Rates with Extended Perioperative Antibiotics and Adjuvant Corticosteroids in Biliary Atresia.

Goh L, Phua K, Low Y, Chiang L, Yong C, Chiou F Pediatr Gastroenterol Hepatol Nutr. 2021; 24(4):366-376.

PMID: 34316471 PMC: 8279824. DOI: 10.5223/pghn.2021.24.4.366.